Related Experiment Video
Updated: Sep 16, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Ivabradine Use in Premature Infants With Accelerated Idioventricular Rhythm
Nawin L Ramdat Misier1,2, Pezad N Doctor1, Kaitlin Tindel3
1Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Introduction:
Ivabradine has been recently introduced to treat focal atrial tachycardia and junctional ectopic tachycardia in children. Its use for treating ventricular tachyarrhythmias, specifically accelerated idioventricular rhythm (AIVR), remains limited.
Methods And Results:
We report two cases of premature infants with AIVR successfully treated with ivabradine as monotherapy after other antiarrhythmic agents had failed. The first infant had a structurally normal heart and the second infant a truncus arteriosus. In both patients, sinus rhythm was restored with ivabradine. Side effects only consisted of brief, hemodynamically insignificant episodes of bradycardia.
Conclusions:
Ivabradine represents a promising antiarrhythmic agent for treating AIVR in preterm infants. Its ability to maintain hemodynamic stability in this age group makes ivabradine an attractive option for managing AIVR, especially in the postoperative setting. Further research is warranted to explore the safety, dosage, and mechanistic action of ivabradine for AIVR in the premature, neonatal infant patient population.
More Related Videos
07:41Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
16:40A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias I: Introduction